Nasdaq

Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.

PARSIPPANY, N.J., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of the first and ...
Yahoo Finance

Viatris Gets FDA Nod for Generic Sandostatin, Shares Regulatory Updates

Viatris Inc. VTRS recently announced four regulatory achievements across multiple stages of its pipeline. These achievements outline the company’s R&D progress in 2025. VTRS will continuously work ...
Healio

Once-monthly octreotide provides sustained acromegaly control with fewer injections

Please provide your email address to receive an email when new articles are posted on . Once-monthly subcutaneous octreotide was associated with persistent control of IGF-I and growth hormone levels ...
ascopubs.org

A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors

Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia Randomized, single-blinded study. Patients with NETs received ...
Yahoo Finance

Viatris Provides Pipeline Update on Four Regulatory Milestones

PITTSBURGH, Dec. 18, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced four recent regulatory milestones spanning across all stages of its global pipeline: ...
Monthly Prescribing Reference

Presence of Glass Particles Prompts Recall of Octreotide Acetate Injection

Syringe and Vials To date, the Company has not received any reports of adverse reactions related to this recall. Mylan Institutional LLC, a Viatris Company, has voluntarily recalled 1 lot of ...